Mark Leong – Executive Chairman – Osteopore (ASX:OSX) is a Singapore-headquartered corporation poised to be a leading medical device company in the region. It is involved in designing, developing and marketing bioresorbable polymer implants for neurosurgical, orthopedic, and maxillofacial surgery use.
Copyright 2023 – Finance News Network
26 Aug 2021 - Chimeric Therapeutics Limited (ASX:CHM) Chief Operating Officer Jennifer Chow talks about the company's licensing of a novel, third-generation CDH17 CAR T cell therapy from the University of Pennsylvania, its recent FDA IND clearance and plans for ongoing growth.
11 Aug 2020 - Regeneus (ASX:RGS) CEO, Leo Lee talks about its collaboration with Kyocera of Japan to market Progenza its cell therapy treatment for anti-inflammatory treatment and repair of damaged or diseased tissue.
21 Oct 2019 - Kingston Resources Limited (ASX:KSN) CFO, Chris Drew, provides an update on the company's Misima and Livingstone gold projects and drill program.
27 Jul 2022 - TerraCom Limited (ASX:TER) Managing Director Danny McCarthy discusses highlights of the company's June quarter results, the recent rains in Queensland, the mine life and run rate of the company's key asset Blair Athol and the outlook for coal.
28 Aug 2020 - VRX Silica Limited (ASX:VRX) Managing Director, Bruce Maluish provides an update on the company's silica sand projects, the market for silica sand, and timelines.
14 Nov 2023 - Explore Chariot Corporation (ASX:CC9) US lithium projects with CEO Shanthar Pathmanathan and geological consultant Dr. Edward Max Baker. Discover the progress at the flagship Black Mountain drill and key milestones ahead.
11 Dec 2020 - Novatti Group Limited (ASX:NOV) Managing Director Peter Cook discusses the company's strategy of partnering with Tier 1 companies, including Ripple, Google Pay and Samsung Pay.
31 Aug 2022 - LBT Innovations Limited (ASX:LBT) CEO and Managing Director Brent Barnes discusses new opportunities for the company's automation technology.
17 Feb 2023 - Radiopharm Theranostics Limited (ASX:RAD) CEO and Managing Director Riccardo Canevari discusses the company's upcoming plans to list on the NASDAQ and provides an update on the its clinical trials.